Business
MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it will present new data from three poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually. “Our data highlight the potent anti-tumor activity and unique tumor homing abilities of iNKT cells, demonstrating their potential as an optimal cell therapy approach,” said Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics. “These data speak to the versatile properties of iNKT cells in both solid and liquid tumors, and infectious disease, which supports our ongoing clinical programs in these settings.” MiNK presentations showcase data on clinical stage, allogeneic iNKT cell therapy, agenT-797, including data on clinical persistence and activity, preclinical anti-tumor activity and tissue distribution. Data also address the tumor-killing potential of engineered iNKT cells as generated by leveraging a proprietary CAR platform. Taken together, these data underscore the potential of agenT-797 in solid tumors, liquid malignancies, and life-threatening infectious diseases. Presentation Details: Abstract title: Persistence and tissue distribution of AgenT-797 – a native allogeneic iNKT cell-therapy drug product (NCT04582201 and NCT04754100)Abstract number: 400Presenting author: Marco Purbhoo Abstract title: AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft modelsAbstract number: 205Presenting author: Burcu Yigit Abstract title: Identification and characterization of an allogeneic iNKT-CAR targeting BCMAAbstract number: 135Presenting author: Xavier Michelet Full text of the abstracts will be available on the SITC website at 8:00 a.m. ET on Tuesday, November 9, and posters will be available in the investor section of the company’s website at 7:00 a.m. ET on November 12. About MiNK TherapeuticsMiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant na...